AD036
Phase 2Small molecule
AD036 is one of 76 small molecule programs targeting Obstructive Sleep Apnea. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
149 competitors in Obstructive Sleep Apnea
#DrugCompanyPhaseTrials
1Mounjaro
Eli LillyPhase 3
Farxiga
AstraZenecaPhase 3
Foundayo
Eli LillyPhase 3
Asmanex
NovartisPhase 3
MS Contin
Merck & Co.Phase 3
Lunesta
Akero TherapeuticsPhase 3
MS Contin
HHikma Pharmaceuticals LLC
Phase 3
Ketalar
AAultman Health Foundation
Phase 3
Imovane
TTaisho Pharmaceutical Co., Ltd.
Phase 3
Sunosi
AAxsome Therapeutics, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Obstructive Sleep Apnea2 trials
Sleep Disorder1 trial
Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing
Completed·—·Phase 2·NCT04611750·53 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AD036. EMBL-EBI & Wellcome Sanger Institute.
- [4]